Related Experiment Video
Updated: Jun 30, 2026
07:12
Evaluation of Cerebral Blood Flow Autoregulation in the Rat Using Laser Doppler Flowmetry
Published on: January 19, 2020
Dexmedetomidine weakens dynamic cerebral autoregulation as assessed by transfer function analysis and the thigh cuff
Yojiro Ogawa1, Ken-ichi Iwasaki, Ken Aoki
1Department of Social Medicine, Nihon University School of Medicine, Tokyo, Japan.
Anesthesiology
|September 25, 2008
Summary
Dexmedetomidine weakens cerebral blood flow regulation, contrary to expectations. This drug may worsen blood flow reductions during drops in blood pressure, posing risks for patients with circulation issues.
Area of Science:
- Anesthesiology
- Critical Care Medicine
- Neuroscience
Background:
- Dexmedetomidine is used in ICUs for patients with compromised circulation.
- It may decrease cerebral blood flow (CBF) if dynamic cerebral autoregulation is impaired.
- Authors hypothesized dexmedetomidine enhances dynamic cerebral autoregulation.
Purpose of the Study:
- To investigate the effect of dexmedetomidine on dynamic cerebral autoregulation.
- To determine if dexmedetomidine strengthens or weakens cerebral blood flow regulation.
Main Methods:
- Randomized, double-blind, crossover study with 14 healthy males.
- Administered placebo, low-dose, and high-dose dexmedetomidine.
- Assessed dynamic cerebral autoregulation using transfer function analysis and thigh cuff method.
Main Results:
- Dexmedetomidine decreased CBF velocity and mean blood pressure.
- Alterations in dynamic cerebral autoregulation observed in low-frequency ranges.
- Impaired restoration of CBF velocity after induced blood pressure decrease.
Conclusions:
- Dexmedetomidine weakens dynamic cerebral autoregulation.
- Restoration of CBF velocity is delayed by dexmedetomidine.
- May increase risk of sustained CBF reduction during hypotension.
